Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. is advancing its IPO process on the Hong Kong Stock Exchange, aiming to become the first company in the field of medical imaging large models, with significant revenue growth driven by its unique market position and favorable policies [1][2]. Group 1: Company Overview - Established in 2016, Deshi Biotechnology focuses on AI in medical imaging and smart equipment, offering a diverse product portfolio including six software products, three commercial medical devices, four main reagents and consumables, and two technology licensing products [2]. - The core product, AI AutoVision®, specializes in intelligent analysis of chromosome karyotypes, having completed clinical trials and received recognition as a Class III innovative medical device from the National Medical Products Administration [2]. Group 2: Technology and Innovation - The success of AI AutoVision® is supported by the underlying technology platform iMedImage™, which enhances product functionality and cross-scenario applications, covering 19 types of medical imaging modalities and over 90% of clinical scenarios [3]. - iMedImage™ is noted as the largest medical imaging base model globally, integrating pre-trained medical imaging technology, thus overcoming limitations of disease-specific and modality-specific small models [3]. Group 3: Market Potential - The AI medical imaging market in China is projected to grow from 2.4 billion yuan in 2024 to 40.1 billion yuan by 2030, with a compound annual growth rate of 60.2% [4]. - Policy support is evident, with the National Health Commission and other departments promoting AI medical imaging applications, aiming for widespread clinical diagnostic services in hospitals by 2030 [4]. Group 4: Funding and Future Plans - Deshi Biotechnology has secured investments from various institutions and plans to use IPO proceeds primarily for the development and commercialization of AI AutoVision®, as well as for other software and medical device R&D [4].

Group 1 - The China Securities Regulatory Commission has issued a notice regarding Hangzhou Deshi Biotechnology Co., Ltd.'s overseas issuance and domestic unlisted shares "full circulation" filing, with plans to issue no more than 31,004,000 overseas listed common shares and list on the Hong Kong Stock Exchange [1][3] - Deshi Biotechnology, founded in 2016, is a leading company in the field of medical imaging AI and intelligent equipment, with significant growth expected in its bidding quantity and amount for 2025 compared to 2024, indicating strong annual performance growth [1][3] - As a national "specialized and innovative" small giant enterprise, Deshi Biotechnology has invested over 100 million yuan in AI research and development, computing power, and intelligent manufacturing, further solidifying its competitiveness in the medical imaging AI and intelligent equipment sector [1][3] Group 2 - According to NVIDIA's forecast, the global medical imaging intelligence market is expected to exceed 100 billion USD by 2030 [2][4] - The National Health Commission and other departments have issued implementation opinions to promote and standardize the application of "AI + healthcare," aiming for basic coverage of intelligent auxiliary applications in grassroots diagnosis and treatment by 2030, with a push for secondary hospitals to widely adopt AI technologies in medical imaging diagnosis and clinical decision-making [2][4] - Deshi Biotechnology, as an industry leader, is positioned to lead the medical imaging diagnostic industry into the intelligent era [2][4]